Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor

  • 35 Accesses

  • 12 Citations

Summary

The serum concentrations of prostatic secretory protein of 94 amino acid residues (PSP94) as well as those of prostate-specific antigen (PSA) were determined in 40 patients with established prostatic carcinoma, prior to transurethral resection of the prostate. In a comparison with a control group of healthy men (n=40) and a group of patients with histologically established benign prostatic hyperplasia (n=40) no significant differences in PSP94 serum concentrations between the groups were observed. Similarly, correlations of PSP94 serum concentrations with prostatic carcinoma stages or grades were not detected. In contrast, and as expected, PSA behaved as a prostate tumor marker of known sensitivity and specificity. A correlation of PSP94 and PSA concentrations in sera of patients with benign prostatic hyperplasia and/or prostatic carcinoma could not be verified. PSP94 apparently does not fulfill the criteria of a serum marker for monitoring adenomas and/or carcinomas of the prostate.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Abrahamsson P-A, Lilja H, Falkmer S, Wadström LB (1988) Immunohistochemical distribution of the three predominant secretory proteins in the parenchyma of hyperplastic and neoplastic prostate glands. Prostate 12:39

  2. 2.

    Abrahamsson PA, Andersson C, Björk T, Fernlund P, Lilja H, Murne A, Weiber H (1989) Radioimmunoassay of β-microseminoprotein, a prostatic-secreted protein present in sear of both men and women. Clin Chem 35:1497

  3. 3.

    Babaian RJ, Camps JL, Frangos DN, Ramirez EI, Tenney DM, Hassell JS, Fritsche HA Jr (1991) Monoclonal prostate-specific antigen in untreated prostate cancer. Cancer 67:2200

  4. 4.

    Bilhartz DL, Tindall DJ, Oesterling JE (1991) Prostate-specific antigen and prostatic acid phosphatase: biomolecular and physiologic characteristics. Urology 38:95

  5. 5.

    Brar A, Mbikay M, Sirois F, Fournier S, Seidah NG, Chrétien M (1988) Localization of the human prostatic secretory protein PSP94 and its mRNA in the epithelial cells of the prostate. J Androl 9:253

  6. 6.

    Brawer MK, Rennels MA, Nagle RB, Schifman R, Gaines JA (1989) Serum prostate-specific antigen and prostate pathology in men having simple prostatectomy. Am J Clin Pathol 92:760

  7. 7.

    Dieijen-Visser MP van, Delaere KPJ, Gijzen AHJ, Brombacher PJ (1988) A comparative study on the diagnostic value of prostatic acid phosphatase (PAP) and prostatic specific antigen (PSA) in patients with carcinoma of the prostate gland. Clin Chim Acta 174:131

  8. 8.

    Dubé JY, Frenette G, Paquin R, Chapdelaine P, Tremblay J, Tremblay RR, Lazure C, Seidah N, Chrétien M (1987) Isolation from human seminal plasma of an abundant 16-kDa protein originating from the prostate, its identification with a 94-residue peptide originally described as β-inhibin. J Androl 8:182

  9. 9.

    Dubé JY, Pelletier G, Gagnon P, Tremblay RR (1987) Immunohistochemical localization of a prostatic secretory protein of 94 amino acids in normal prostatic tissue, in primary prostatic tumors and in their metastases. J Urol 138:883

  10. 10.

    Frazier HA, Humphrey PA, Burchette JL, Paulson DF (1992) Immunoreactive prostatic specific antigen in male periurethral glands. J Urol 147:246

  11. 11.

    Gagnon S, Têtu B, Dubé JY, Tremblay RR (1990) Expression of Zn-alpha2-glycoprotein and PSP-94 in prostatic adenocarcinoma. Am J Pathol 136:1147

  12. 12.

    Hermanek P, Sobin LH (1987) TNM classification of malignant tumors 4th edn. Springer, Berlin Heidelberg New York, pp 124–129

  13. 13.

    Ito Y, Tsuda R, Kimura H (1989) Ultrastructural localizations of β-microseminoprotein, a prostate-specific antigen, in human prostate and sperm: comparison with γ-seminoprotein, another prostate-specific antigen. J Lab Clin Med 114:272

  14. 14.

    Ramme H von der, Krauhs E, Aumüller G, Scheit K-H (1990) Characterization of a monoclonal antibody specific for prostatic secretory protein of 94 amino acids (PSP94) and development of a two-site binding enzyme immunoassay for PSP94. Clin Chim Acta 187:207

  15. 15.

    Kammer H von der, Scheit KH, Weidner W, Cooper TG (1991) The evaluation of markers of prostatic function. Urol Res 19:343

  16. 16.

    Kamoshida S, Tsutsumi Y (1990) Extraprostatic localization of prostatic acid phosphatase and prostate-specific antigen. Hum Pathol 21:1108

  17. 17.

    Lilja H, Abrahamsson PA (1988) Three predominant proteins secreted by the human prostate gland. Prostate 12:29

  18. 18.

    Lilja H, Christensson A, Dahlén U, Matikainen M-T, Nilsson O, Pettersson K, Lövgren T (1991) Prostate-specific antigen in serum occurs predominantly in complex with α1-antichymotrypsin. Clin Chem 37:1618

  19. 19.

    Oesterling JE (1991) Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol 145:907

  20. 20.

    Pretlow TG, Pretlow TP, Yang B, Kaetzel CS, Delmoro CM, Kamis SM, Bodner DR, Kursh E, Resnick MI, Bradley EL Jr (1991) Tissue concentrations of prostate-specific antigen in prostatic carcinoma and benign prostatic hyperplasia. Int J Cancer 49:645

  21. 21.

    Qiu S-D, Young CY-F, Bilhartz DL, Prescott JL, Farrow GM, He W-W, Tindall DJ (1990) In situ hybridization of prostate-specific antigen mRNA in human prostate. J Urol 144:1550

  22. 22.

    Sachs L (1988) Statistische Methoden: Planung und Auswertung. Springer, Berlin Heidelberg New York, S 60

  23. 23.

    Semjonow A, Hamm M, Rathert P (1992) Half-life of prostate-specific antigen after radical prostatectomy: the decisive predictor of curative treatment? Eur Urol 21:200

  24. 24.

    Shivaji S, Scheit K-H, Bhargava PM (1990) Proteins of seminal plasma. Wiley, New York, p 125

  25. 25.

    Simm B, Gleeson M (1991) Storage conditions for serum for estimating prostate-specific antigen. Clin Chem 37:113

  26. 26.

    Stamey TA (1990) Die Rolle des prostataspezifischen Antigens bei der Diagnose und Behandlung des Prostatakarzinoms. Urologe [A] 29:52

  27. 27.

    Tremblay J, Frenette G, Tremblay RR, Dupont A, Thabet M, Dubé JY (1987) Excretion of three major prostatic secretory proteins in the urine of normal men and patients with benign prostatic hypertrophy or prostate cancer. Prostate 10:235

  28. 28.

    Ulvsbäck M, Lindström C, Weiber H, Abrahamsson PA, Lilja H, Lundwall A (1989) Molecular cloning of a small prostate protein, known as β-microseminoprotein, PSP94 or β-inhibin, and demonstration of transeripts in non-genital tissues. Biochem Biophys Res Commun 164:1310

  29. 29.

    Voogt HJ de, Soloway MS, Altwein JE (1988) Prostatakarzinom: Aktuelle Therapiemodalitäten. Pfützer, München, S20–21

  30. 30.

    Weiber H, Andersson C, Murne A, Rannevik G, Lindström C, Lilja H, Fernlund P (1990) β-Microseminoprotein is not a prostate-specific protein. Am J Pathol 137:593

Download references

Author information

Rights and permissions

Reprints and Permissions

About this article

Cite this article

von der Kammer, H., Jurincic-Winkler, C., Horlbeck, R. et al. The potential use of prostatic secretory protein of 94 amino acid residues (PSP94) as a serum marker for prostatic tumor. Urol. Res. 21, 227–233 (1993). https://doi.org/10.1007/BF00590041

Download citation

Key words

  • Prostatic cancer markers
  • Prostatic secretory protein
  • PSP94
  • Prostate-specific antigen